BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11872627)

  • 21. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.
    Tang D; Sivko GS; DeWille JW
    Breast Cancer Res Treat; 2006 Jan; 95(2):161-70. PubMed ID: 16322893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3.
    Aoyama T; Okamoto T; Nagayama S; Nishijo K; Ishibe T; Yasura K; Nakayama T; Nakamura T; Toguchida J
    J Biol Chem; 2004 Jul; 279(27):28789-97. PubMed ID: 15107420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells.
    Côté S; Sinnett D; Momparler RL
    Anticancer Drugs; 1998 Oct; 9(9):743-50. PubMed ID: 9840718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.
    Oue N; Shigeishi H; Kuniyasu H; Yokozaki H; Kuraoka K; Ito R; Yasui W
    Int J Cancer; 2001 Sep; 93(6):805-9. PubMed ID: 11519041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
    Patel AC; Anna CH; Foley JF; Stockton PS; Tyson FL; Barrett JC; Devereux TR
    Carcinogenesis; 2000 Sep; 21(9):1691-700. PubMed ID: 10964101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines.
    Yanagawa N; Tamura G; Honda T; Endoh M; Nishizuka S; Motoyama T
    Clin Cancer Res; 2004 Apr; 10(7):2447-51. PubMed ID: 15073123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells.
    Nishimura M; Saito T; Yamasaki H; Kudo R
    Carcinogenesis; 2003 Oct; 24(10):1615-23. PubMed ID: 12896902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
    Hartsough MT; Clare SE; Mair M; Elkahloun AG; Sgroi D; Osborne CK; Clark G; Steeg PS
    Cancer Res; 2001 Mar; 61(5):2320-7. PubMed ID: 11280805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
    Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
    Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma.
    Liu XQ; Chen HK; Zhang XS; Pan ZG; Li A; Feng QS; Long QX; Wang XZ; Zeng YX
    Int J Cancer; 2003 Aug; 106(1):60-5. PubMed ID: 12794757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer.
    Kikuchi T; Itoh F; Toyota M; Suzuki H; Yamamoto H; Fujita M; Hosokawa M; Imai K
    Int J Cancer; 2002 Jan; 97(3):272-7. PubMed ID: 11774276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
    Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
    Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer.
    Han LL; Hou L; Zhou MJ; Ma ZL; Lin DL; Wu L; Ge YL
    J Biomed Sci; 2013 Jul; 20(1):52. PubMed ID: 23899187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of a CpG island within the uroplakin Ib promoter: a possible mechanism for loss of uroplakin Ib expression in bladder carcinoma.
    Varga AE; Leonardos L; Jackson P; Marreiros A; Cowled PA
    Neoplasia; 2004; 6(2):128-35. PubMed ID: 15140401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter methylation assay of SASH1 gene in breast cancer.
    Sheyu L; Hui L; Junyu Z; Jiawei X; Honglian W; Qing S; Hengwei Z; Xuhui G; Qinghe X; Lin H
    J BUON; 2013; 18(4):891-8. PubMed ID: 24344014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter methylation of cyclin D2 gene in gastric carcinoma.
    Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
    Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status.
    Xiong J; Epstein RJ
    Mol Cancer Ther; 2009 Apr; 8(4):779-85. PubMed ID: 19372550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine.
    Bovenzi V; Lê NL; Côte S; Sinnett D; Momparler LF; Momparler RL
    Anticancer Drugs; 1999 Jun; 10(5):471-6. PubMed ID: 10477167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.